mdx-1411
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00656734)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD70 antigenCROSS-LINKING AGENT
CD70 cross-linking agent
- CD70 antigenINHIBITOR
CD70 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109492 ↗
Also known as
- mdx 1411
- mdx-1411
- mdx-1411
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00730652 | Phase 1 | May 1, 2009 | Bristol-Myers Squibb, Medarex |
| NCT00656734 | Phase 1 | Apr 1, 2008 | Bristol-Myers Squibb |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2008 |
| Medarex | For profit | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1